Partners

Strategic partnerships will allow us to reach our goals

Grants

January 1, 2019
ERC Grant

New data generation
& Application of 2
European Patents

January 1, 2019
January 1, 2019
ERC PoC

PoC Validation

January 1, 2019
January 1, 2019
DTS

Biomarker Validation

January 1, 2019
January 1, 2019
MAP Program
EADA Business school

Market analysis &
Financial validation

January 1, 2019
January 1, 2019
CRAASH Barcelona

Program that helps European research teams launch successful diagnostic innovations to improve health and patient care

January 1, 2019
January 1, 2019
FIPSE

Ayudas para financiar estudios de viabilidad de las innovaciones en Salud

January 1, 2019

Collaborators

ABG Intellectual property

Attorney Officer

Vantum corporate

Chief Financial Officer

MOLOMICS

Computational Drug Discovery

Investors

AtG’s business model consists of de-risking AtG-101 and its Companion Diagnostic from a Proof of Concept Development Stage into a successful Phase I/II product and then Licensing it to a Pharmaceutical company.

AtG is currently looking for investors in order to fund the preclinical development of AtG-101.

Would it be you?